The Paradise Ultrasound Renal Denervation (uRDN) system becomes the first and only ultrasound-based renal denervation (RDN) therapy to be granted a distinct category and device code for incremental Outpatient Transitional Pass-through (TPT) payment by CMS,

The new ESC Guidelines for Management of Elevated Blood Pressure and Hypertension were presented at the ESC Congress in London and reinforce the safety and effectiveness of renal denervation, recommending its consideration as a treatment

Statement from the AHA in support of Renal Denervation as a hypertension therapy option provides reinforcement that the treatment can have a meaningful positive impact on the wellbeing of people with resistant or uncontrolled high

Availability of the New Technology Add-on Payment (NTAP) will improve access to innovative ultrasound hypertension therapy for patients across the country   Palo Alto, Calif. – August 12, 2024 – Recor Medical, Inc. (“Recor”) and

Durham VA Health Care System in North Carolina is the first site in US to enroll and treat patients in the study collecting real-world data on long-term safety and effectiveness of the Paradise® Ultrasound Renal

Palo Alto, California (May 17, 2024) – Hypertension, or high blood pressure, affects nearly half of all Americans and more than one billion people worldwide.  Hypertension is known as the “silent killer” because many people

Al Qassimi Hospital Sharjah becomes first in the Middle East to treat patients with innovative new device-based option to help reduce blood pressure. PALO ALTO, Calif. — Apr. 18, 2024 — Recor Medical, Inc. (“Recor”)

Innovative new treatment option for patients with uncontrolled hypertension now available in the United States   PALO ALTO, Calif. — Nov. 10, 2023 — Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices

Approval of the Paradise™ Ultrasound Renal Denervation system makes innovative hypertension treatment available for the first time in the U.S. Palo Alto, Calif. – November 7, 2023 – Recor Medical, Inc. (“Recor”) and its parent company, Otsuka

Analysis shows a maintained blood pressure lowering effect with fewer added medications following treatment with the Paradise Ultrasound Renal Denervation system   Palo Alto, Calif. – October 26, 2023 – Recor Medical, Inc. (“Recor”) and its parent company,

Presentations include late-breaking results of six-month pooled analysis of data from the RADIANCE™ Global Clinical Trial Program   Palo Alto, Calif. – October 20, 2023 – Recor Medical, Inc. (“Recor”), a subsidiary of Otsuka Medical Devices Co.,

The new guidelines are designed to serve as a resource on the latest scientific evidence for healthcare professionals around the world who treat people with hypertension.

Study results showed that the Paradise Ultrasound Renal Denervation (uRDN) System successfully reduced blood pressure compared to sham.

Ms. Barghout brings more than 20 years of experience leading global businesses in the medical device industry.

The Paradise uRDN System is designed to reduce sympathetic nerve activity by denervating nerves which surround the renal arteries with the goal of reducing blood pressure.

The results come from analysis of the pooled data from ReCor’s RADIANCE Global Clinical Trial Program.